Let's talk medical research

With technology advancing at a rapid pace, clinical trial sponsors and sites have been forced to rethink the avenues they use to optimize clinical trials. This has become especially apparent during the COVID-19 pandemic — for clinical trials to stay on track, they have to adopt new ways of conducting research while maintaining data integrity and patient safety. At the same time, patient ...

A flare-up is the reappearance of disease symptoms. And for people living with ulcerative colitis (UC), an inflammatory bowel disease (IBD), flare-ups can be unpredictable, lasting hours, days, or weeks. 

The 10th anniversary of DPharm, a conference that brings clinical research professionals together to share innovations in the clinical trials field, looked a little different than previous years. Due to COVID-19, the gathering happened online, and much of the focus was on navigating the clinical trials arena in light of the pandemic.

Biliary tract cancer (which includes intrahepatic cholangiocarcinoma or bile duct cancer, extrahepatic cholangiocarcinoma, and gallbladder cancer) is a rare form of cancer that develops in the bile duct system, which connects the liver, gallbladder, and small intestine, moving bile to the small intestine.

By some estimations, 80% of clinical trials are delayed or closed because researchers can’t find enough patients to take part in their clinical trials. This, of course, means that trial sponsors are losing money and sites are wasting time screening ineligible patients. But, it also means that countless patients continue to wait for new and potentially better treatment options.

As of September 2020, there have been over 30 million COVID-19 cases worldwide, with nearly 7 million cases in the United States alone. The impact of this global pandemic is widespread, ranging from how we conduct ourselves in public to the ways in which we seek healthcare. 

Living with myasthenia gravis, a rare neuromuscular disorder characterized by progressive weakness of the skeletal muscles, can be difficult. The symptoms, which include trouble talking, facial paralysis, difficulty breathing due to muscle weakness, fatigue, drooping of eyelids, and double vision, can make those living with the condition feel very isolated.

Successful clinical trial advertising engages patients and encourages them to join your trial, while adhering to the strict guidelines laid out by the Food and Drug Administration (FDA). Getting creative within these confines can be a challenge, but with the right research and strategy, your ads can strike the appropriate balance.

Living with lupus can be difficult. It’s an “invisible illness” — meaning those around you can’t see your fatigue or your muscle and joint pain or any of the many other symptoms. This can be a lonely experience, and that’s why it’s so important for people with lupus to connect with others who have the condition as well. 

The spread of COVID-19 has caused a public health frenzy throughout the world. And, while COVID-19 clinical research remains top of mind for many, the pandemic has caused clinical research in other areas to face a barrage of disruption to typical research flows.